Introduction to Gene Therapy

  • Ayman Al-Hendy
  • Salama A. Salama

Gene therapy is broadly defined as the delivery or transferof genetic material to target cells for therapeutic purposes. Elucidation of the molecular bases of inherited diseases as well as acquired diseases, such as cancer, allows for the possibility of therapeutic interventions at the molecular level. The therapeutic benefits may be achieved by, interfering with gene function, restoring lost function, or initiating a new function in the target cells. Current methods of gene transfer include the use of viral and non-viral vectors [1–5]. Viral vectors accomplish gene transfer directly by viral-mediated infection.


Gene Therapy Adenoviral Vector Uterine Fibroid Bystander Effect Therapeutic Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Glossary of Terms and Acronyms


adeno-associated viruses


type of adenovirus


adenoviral vector that expresses a dominant negative ER mutant


adenovirus expressing the marker gene β-lactamase


aldehyde dehydrogenase class 1 gene


basic fibroblast growth factor


calcium chloride


coxsackie-adenovirus receptor


cytosine deaminase plus 5-fluorocytosine




conditionally replicative adenoviruses


deoxyribonucleic acid


cell line derived from Eker rat leiomyoma


estrogen receptor


estrogen receptor element


estrogen receptor mutant




herpes simplex virus


herpes simplex virus-thymidine kinase


human leiomyoma cell line


multidrug resistance gene


multiplicity of infection


platelet-derived endothelial growth factor


ribonucleic acid


small interfering RNA


thymidine kinase – ganciclovir


tumor necroses factor


TNF apoptosis-inducing ligand


vascular endothelial growth factor


  1. 1.
    Mullen CA, Blaese RM. Gene therapy of cancer. Canc Chemother Biol Response Modif 1994; 15:176–89.Google Scholar
  2. 2.
    Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270:404–10.Google Scholar
  3. 3.
    Blaese M, Blankenstein T, Brenner M, et al. Vectors in cancer therapy: how will they deliver? Cancer Gene Ther 1995; 2:291–7.Google Scholar
  4. 4.
    Ali M, Lemoine NR, Ring CJ. The use of DNA viruses as vectors for gene therapy. Gene Ther 1994; 1:367–84.PubMedGoogle Scholar
  5. 5.
    Schofield JP, Caskey CT. Non-viral approaches to gene therapy. BMJ 51; 56–71.Google Scholar
  6. 6.
    Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861–70.Google Scholar
  7. 7.
    Munkonge FM, Dean DA, Hillery E, et al. Emerging significance of plasmid DNA nuclear import in gene therapy. Adv Drug Deliv Rev 2003; 55:749–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Mattaj IW, Englmeier L. Nucleocytoplasmic transport: the soluble phase. Annu Rev Biochem 1998; 67:265–06.Google Scholar
  9. 9.
    Gallo-Penn AM, Shirley PS, Andrews JL, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001; 97:107–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Lechardeur D, Sohn KJ, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther 1999; 6:482–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Hendrie PC, Russell DW. Gene targeting with viral vectors. Mol Ther 2005; 12:9–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Benn SI, Whitsitt JS, Broadley KN, et al. Particle-mediated gene transfer with transforming growth factor-beta1 cDNAs enhances wound repair in rat skin. J Clin Invest 1996; 98:2894–02.PubMedCrossRefGoogle Scholar
  13. 13.
    Mahvi DM, Burkholder JK, Turner J, et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996; 7:1535–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Andree C, Swain WF, Page CP, et al. In vivotransfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci U S A 1994; 91:12188–92.Google Scholar
  15. 15.
    Sun L, Xu L, Chang H, et al. Transfection with aFGF cDNA improves wound healing. J Invest Dermatol 1997; 108:313–18.PubMedCrossRefGoogle Scholar
  16. 16.
    Larregina AT, Watkins SC, Erdos G, et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 2001; 8:608–17.PubMedCrossRefGoogle Scholar
  17. 17.
    Loehr BI, Willson P, Babiuk LA, et al. Gene gun-mediated DNA immunization primes development of mucosal immunity against bovine herpesvirus 1 in cattle. J Virol 2000; 74: 6077–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Davidson JM, Krieg T, Eming SA. Particle-mediated gene therapy of wounds. Wound Repair Regen 2000; 8:452–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Andre F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004; 11:33–42.CrossRefGoogle Scholar
  20. 20.
    Mir LM, Moller PH, Andre F, et al. Electric pulse-mediated gene transfer to various animal tissues. Adv Genet 2005; 54:83–114.PubMedCrossRefGoogle Scholar
  21. 21.
    Belehradek M, Domenge C, Luboinski B, et al. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993; 72:3694–700.Google Scholar
  22. 22.
    Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998; 77:2336–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 29:371–87.PubMedCrossRefGoogle Scholar
  24. 24.
    Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene transfer. Nat Rev Drug Discov 2005; 4:581–93.PubMedCrossRefGoogle Scholar
  25. 25.
    Abdelhady HG, Allen S, Davies MC, et al. Direct real-time molecular scale visualisation of the degradation of condensed DNA complexes exposed to DNase I. Nucleic Acids Res 2003; 31:4001–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Worgall S. A realistic chance for gene therapy in the near future. Pediatr Nephrol 2005; 20:118–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Huang L, Viroonchatapan E. Introduction. In Huang L, Hung MC, Wagner E, editors. Non-viral Vectors for Gene Therapy. San Diego: Academic Press, 1999:3–22.Google Scholar
  28. 28.
    Barron LG, Szoka FC. The preplexing delivery mechanism of lipoplexes. In Huang L, Hung MC, Wagner E, editors. Non-viral Vectors for Gene Therapy. San Diego: Academic Press, 1999: 229–66.Google Scholar
  29. 29.
    Xu L, Pirollo KF, Chang EH. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 2001; 74:115–28.PubMedCrossRefGoogle Scholar
  30. 30.
    Culver KW, Vickers TM, Lamsam JL, et al. Gene therapy for solid tumors. BMJ 1995; 51:192–204.Google Scholar
  31. 31.
    Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185–93.PubMedCrossRefGoogle Scholar
  32. 32.
    Check E. Second cancer case halts gene-therapy trials. Nature 2003; 421:305.PubMedCrossRefGoogle Scholar
  33. 33.
    Barquinero J, Eixarch H, Perez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther 2004; 11:3–9.CrossRefGoogle Scholar
  34. 34.
    Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74:711–38.PubMedCrossRefGoogle Scholar
  35. 35.
    Hallenbeck PL, Stevenson SC. Targetable gene transfer vectors. Adv Exp Med Biol 2000; 465:37–46.PubMedCrossRefGoogle Scholar
  36. 36.
    Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3:499–03.PubMedCrossRefGoogle Scholar
  37. 37.
    Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005; 37:33–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Gomez-Navarro J, Curiel DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol 2000; 1:148–58.PubMedCrossRefGoogle Scholar
  39. 39.
    Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18:723–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Hermiston T. Gene transfer from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105:1169–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000; 105:847–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Kim M, Zinn KR, Barnett BG, et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38:1917–26.PubMedCrossRefGoogle Scholar
  43. 43.
    Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575:1–14.PubMedGoogle Scholar
  44. 44.
    Stone D, Furthmann A, Sandig V, et al. The complete nucleotide sequence, genome organization, and origin of human adenovirus type 11. Virology 2003; 309:152–65.PubMedCrossRefGoogle Scholar
  45. 45.
    Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77:8263–71.PubMedCrossRefGoogle Scholar
  46. 46.
    Goldman CK, Soroceanu L, Smith N, et al. In vitroand in vivogene transfer mediated by a synthetic polycationic amino polymer. Nat Biotechnol 1997b; 15:462–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Goldman CK, Rogers BE, Douglas JT, et al. Targeted gene transfer to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997a; 57:1447–51.PubMedGoogle Scholar
  48. 48.
    Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4:2455–61.PubMedGoogle Scholar
  49. 49.
    Stone D, Ni S, Li ZY, et al. Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 2005; 79:5090–104.PubMedCrossRefGoogle Scholar
  50. 50.
    Dai Y, Schwarz EM, Gu D, et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401–5.Google Scholar
  51. 51.
    Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 1998; 95:11377–82.Google Scholar
  52. 52.
    Tripathy SK, Black HB, Goldwasser E, et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996; 2:545–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76:2667–75.PubMedCrossRefGoogle Scholar
  54. 54.
    Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 2000; 11:1713–22.PubMedCrossRefGoogle Scholar
  55. 55.
    Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8:341–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Lu B, Makhija SK, Nettelbeck DM, et al. Evaluation of tumor-specific promoter activities in melanoma. Gene Ther 2005; 12: 330–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Glasgow JN, Bauerschmitz GJ, Curiel DT, et al. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr Gene Ther 2004; 4:1–14.PubMedCrossRefGoogle Scholar
  58. 58.
    Zaiss AK, Liu Q, Bowen GP, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76:4580–90.PubMedCrossRefGoogle Scholar
  59. 59.
    Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol 1997; 71:8429–36.PubMedGoogle Scholar
  60. 60.
    Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol 1995; 49:807–38.PubMedCrossRefGoogle Scholar
  61. 61.
    Bowers WJ, Olschowka JA, Federoff HJ. Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy. Gene Ther 2003; 10:941–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Fielding AK. Measles as a potential oncolytic virus. Rev Med Virol 2005; 15:135–42.PubMedCrossRefGoogle Scholar
  63. 63.
    Ponnazhagan S. Parvovirus vectors for cancer gene therapy. Expert Opin Biol Ther 2004; 4:53–64.PubMedCrossRefGoogle Scholar
  64. 64.
    Rosenfeld M, Curiel DT. Gene therapy strategies for novel cancer therapeutics. Curr Opin Oncol 1996; 8:39–47.CrossRefGoogle Scholar
  65. 65.
    Watanabe M, Nasu Y, Kashiwakura Y, et al. Adeno-associated virus 2-mediated intramural prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther 2005; 16:699–710.PubMedCrossRefGoogle Scholar
  66. 66.
    Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 2005; 4:512–17.PubMedCrossRefGoogle Scholar
  67. 67.
    Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994; 32:39–47.PubMedCrossRefGoogle Scholar
  68. 68.
    Barnes MN, Deshane JS, Rosenfeld M, et al. Gene therapy and ovarian cancer: a review. Obstet Gynecol 1997; 89:145–55.PubMedCrossRefGoogle Scholar
  69. 69.
    Greco O, Dachs GU. Gene directed enzyme/pro-drug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187:22–36.PubMedCrossRefGoogle Scholar
  70. 70.
    Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5:153–64.PubMedCrossRefGoogle Scholar
  71. 71.
    Dohring C, Angman L, Spagnoli G, et al. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994; 57:754–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996; 6:5–10.PubMedCrossRefGoogle Scholar
  73. 73.
    Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6:652–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Cowan KH, Moscow JA, Huang H, et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999; 5:1619–28.PubMedGoogle Scholar
  75. 75.
    Takebe N, Zhao SC, Adhikari D, et al. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol Ther 2001; 3:88–96.PubMedCrossRefGoogle Scholar
  76. 76.
    Walker CL, Burroughs KD, Davis B, et al. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Investig 2000; 7:249–56.PubMedCrossRefGoogle Scholar
  77. 77.
    Stewart EA. Uterine fibroids. Lancet 2001; 357:293–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitrofertilization-embryo transfer cycle outcome. Fertil Steril 2001; 75:405–10.PubMedCrossRefGoogle Scholar
  79. 79.
    Hart R, Khalaf Y, Yeong CT, et al. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod 2001; 16:2411–7.PubMedGoogle Scholar
  80. 80.
    Di Lieto A, De Falco M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005; 12:123–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Gentry CC, Okolo SO, Fong LF, et al. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci 2001; 101:691–5.PubMedCrossRefGoogle Scholar
  82. 82.
    Hong T, Shimada Y, Uchida S, et al. Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med 2001; 8:141–8.PubMedGoogle Scholar
  83. 83.
    Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 2000; 108:785–90.PubMedGoogle Scholar
  84. 84.
    Hoffman PJ, Milliken DB, Gregg LC, et al. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 2004;82:639–49.PubMedCrossRefGoogle Scholar
  85. 85.
    Niu H, Simari RD, Zimmermann EM, et al. Nonviral vector-mediated thymidine kinase gene transfer and ganciclovir treatment in leiomyoma cells. Obstet Gynecol 1998; 91:735–40.PubMedCrossRefGoogle Scholar
  86. 86.
    Christman GM, McCarthy JD. Gene therapy and uterine leiomyomas. Clin Obstet Gynecol 2001; 2:425–35.CrossRefGoogle Scholar
  87. 87.
    Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53:5274–83.PubMedGoogle Scholar
  88. 88.
    Marwa K, Salama A, Christman GM, et al. Uterine fibroids gene therapy: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells [Abstract]. J Soc Gynecol Investig 2005; 12:94A.Google Scholar
  89. 89.
    Andersen J. Comparing regulation of the connexin43 gene by estrogen in uterine leiomyoma and pregnancy myometrium. Environ Health Perspect 2000; 108:811–5.PubMedCrossRefGoogle Scholar
  90. 90.
    Al-Hendy A, Lee EJ, Wang HQ, et al. Gene therapy of uterine leiomyomas: Adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004; 191:1621–31.PubMedCrossRefGoogle Scholar
  91. 91.
    Ince BA, Zhuang Y, Wrenn CK, et al. Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem 1993; 268:14026–32.PubMedGoogle Scholar
  92. 92.
    Howe SR, Gottardis MM, Everitt JI, et al. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995; 146: 1568–79.PubMedGoogle Scholar
  93. 93.
    Hodges LC, Hunter DS, Bergerson JS, et al. An in vivo/in vitromodel to assess endocrine disrupting activity of xenoestrogens in uterine leiomyoma. Ann N Y Acad Sci 2001; 948: 100–11.PubMedCrossRefGoogle Scholar
  94. 94.
    Al-Hendy A, Magliocco AM, Al Tweigeri T, et al. Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol 2000; 182:553–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Everitt JI, Wolf DC, Howe SR, et al. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995; 146:1556–67.PubMedGoogle Scholar
  96. 96.
    Cook JD, Walker CL. The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. Curr Mol Med 2004; 4:813–24.PubMedCrossRefGoogle Scholar
  97. 97.
    Houston KD, Hunter DS, Hodges LC, et al. Uterine leiomyomas: mechanisms of tumorigenesis. Toxicol Pathol 2001; 29: 100–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyMeharry Medical College Center for Women Health ResearchNashvilleUSA
  2. 2.Department of Obstetrics & GynecologyUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations